The final, formatted version of the article will be published soon.
PERSPECTIVE article
Front. Public Health
Sec. Health Economics
Volume 12 - 2024 |
doi: 10.3389/fpubh.2024.1383107
Collaboration for New Therapies: Maximising Health and Innovation
Provisionally accepted- 1 Carlos III International School, University Carlos III of Madrid, Getafe, Spain
- 2 Other, Faro, Portugal
- 3 Wifor Institute, Darmstadt, Germany
- 4 Merck (United States), Kenilworth, New Jersey, United States
Introduction Innovative medicines and vaccines can provide direct health benefits to patients and populations by preventing, treating and curing diseases, and also drive wider socioeconomic and productivity gains. However, researching and developing them is complex and risky. Funding for life sciences R&D has different sources: public, charitable/NGO, and private sector. We believe there is consensus that all are required, although there is less understanding about their respective roles, synergies, and funding priorities. The purpose of this paper is to provide an overview of the current life sciences innovation ecosystem in Europe, highlighting challenges for funding and innovation of new therapies and our proposed options to address these. Methods The basis of this paper stems from the reflections made by the co-authors during a webinar with title “Collaboration for new therapies: maximising funding and innovation”, in March 2023, with further targeted literature reviews. Results We identify eight challenges in the European life sciences ecosystem, some closely related, and nine options that we think might be helpful to address them. Each option on its own can have different levels of ‘impact’, but collectively will provide synergies amongst them, and thus maximise their impact. Discussion It is critical to ascertain how the strengths of each actor can be leveraged to bring new medicines/treatments to market, quicker and more efficiently. We need a trusted environment, with strategic collaborations between the public and private sectors, and policy initiatives and incentives should be targeted to strengthen the infrastructure with the aim of fostering such optimal alliances
Keywords: Innovation ecosystem, Life sciences sector, funding, incentives, Research and development
Received: 08 Feb 2024; Accepted: 30 Aug 2024.
Copyright: © 2024 Mestre Ferrandiz, Meulien, Ostwald and Acha. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jorge Mestre Ferrandiz, Carlos III International School, University Carlos III of Madrid, Getafe, Spain
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.